Work

Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin

Year: 2020

Type: article

Abstract: Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin

Source: British Journal of Haematology

DOI: 10.1111/bjh.17029

Authors: Ryan D. Cassaday, David I. Marks, Daniel J. DeAngelo, Elias J. Jabbour, Anjali S. Advani, Susan O’Brien, Tao Wang, Alexander Neuhof, Erik Vandendries, Hagop M. Kantarjian, Wendy Stock, Matthias Stelljes

Institutions: University of Washington, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Cleveland Clinic, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, Pfizer (United States), Pfizer (Germany), University of Chicago, University Hospital Münster

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Pfizer

OpenAlex ID: W3067119682

FWCI: 0.749

Cites: 8

Cited by: 10

Related to: 10